CY1124594T1 - A NOVEL POLYMORPHIC FORM OF N-[2-(6-FLUORO-L-INDOL-3-YL)ETHYL]-3-(2,2,3,3-TETRAFLUOROPROPXY)BENZYLAMINE HYDROCHLORIDE FOR THE INDUCTION OF ALZHEIMER - Google Patents

A NOVEL POLYMORPHIC FORM OF N-[2-(6-FLUORO-L-INDOL-3-YL)ETHYL]-3-(2,2,3,3-TETRAFLUOROPROPXY)BENZYLAMINE HYDROCHLORIDE FOR THE INDUCTION OF ALZHEIMER

Info

Publication number
CY1124594T1
CY1124594T1 CY20211100897T CY211100897T CY1124594T1 CY 1124594 T1 CY1124594 T1 CY 1124594T1 CY 20211100897 T CY20211100897 T CY 20211100897T CY 211100897 T CY211100897 T CY 211100897T CY 1124594 T1 CY1124594 T1 CY 1124594T1
Authority
CY
Cyprus
Prior art keywords
indol
fluoro
ethyl
tetrafluoropropxy
alzheimer
Prior art date
Application number
CY20211100897T
Other languages
Greek (el)
Inventor
Kristine Birklund Andersen
Michael Harold Rock
Heidi Lopez DE DIEGO
Frans Dennis THERKELSEN
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1124594T1 publication Critical patent/CY1124594T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η παρούσα εφεύρεση σχετίζεται με καινοφανή πολυμορφική μορφή της υδροχλωρικής Ν-[2-(6-φθορο-1Η-ινδολ-3-υλ)αιθυλ]-3-(2,2,3,3,- τετραφθοροπροποξυ)βενζυλαμίνης.The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3,-tetrafluoropropoxy)benzylamine hydrochloride.

CY20211100897T 2014-07-04 2021-10-15 A NOVEL POLYMORPHIC FORM OF N-[2-(6-FLUORO-L-INDOL-3-YL)ETHYL]-3-(2,2,3,3-TETRAFLUOROPROPXY)BENZYLAMINE HYDROCHLORIDE FOR THE INDUCTION OF ALZHEIMER CY1124594T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04
PCT/EP2015/065176 WO2016001398A1 (en) 2014-07-04 2015-07-03 Novel polymorphic form of n-[2-(6-fluoro-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer's

Publications (1)

Publication Number Publication Date
CY1124594T1 true CY1124594T1 (en) 2022-07-22

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100897T CY1124594T1 (en) 2014-07-04 2021-10-15 A NOVEL POLYMORPHIC FORM OF N-[2-(6-FLUORO-L-INDOL-3-YL)ETHYL]-3-(2,2,3,3-TETRAFLUOROPROPXY)BENZYLAMINE HYDROCHLORIDE FOR THE INDUCTION OF ALZHEIMER

Country Status (41)

Country Link
US (1) US10071963B2 (en)
EP (1) EP3164385B1 (en)
JP (2) JP6643330B2 (en)
KR (1) KR102399374B1 (en)
CN (3) CN112961095A (en)
AP (1) AP2016009643A0 (en)
AR (1) AR101109A1 (en)
AU (1) AU2015282909B2 (en)
CA (1) CA2951794C (en)
CL (1) CL2017000002A1 (en)
CO (1) CO2017000019A2 (en)
CR (1) CR20160605A (en)
CY (1) CY1124594T1 (en)
DK (1) DK3164385T3 (en)
DO (1) DOP2017000001A (en)
EA (1) EA035894B1 (en)
EC (1) ECSP17000222A (en)
ES (1) ES2893619T3 (en)
GE (1) GEP20227368B (en)
HR (1) HRP20211596T8 (en)
HU (1) HUE056368T2 (en)
IL (1) IL249428B (en)
JO (1) JO3639B1 (en)
LT (1) LT3164385T (en)
MA (1) MA40345B1 (en)
MX (1) MX2016016895A (en)
MY (1) MY190715A (en)
NZ (1) NZ727251A (en)
PE (1) PE20170522A1 (en)
PH (1) PH12016502477B1 (en)
PL (1) PL3164385T3 (en)
PT (1) PT3164385T (en)
RS (1) RS62380B1 (en)
RU (1) RU2016151637A (en)
SG (1) SG11201610334XA (en)
SI (1) SI3164385T1 (en)
SV (1) SV2016005353A (en)
TN (1) TN2016000549A1 (en)
TW (1) TWI665188B (en)
UA (1) UA121547C2 (en)
WO (1) WO2016001398A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292758T3 (en) * 2001-03-29 2008-03-16 Eli Lilly And Company N- (2-ARILETIL) BENCILAMINS AS ANTAGONISTS OF THE 5-HT6 RECEIVER.
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (en) 2012-09-09 2020-07-05 H Lundbeck As Pharmaceutical compositions for treating alzheimer's disease
CN105175307A (en) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054 hydrochloride crystal form A, preparation method and uses thereof

Also Published As

Publication number Publication date
LT3164385T (en) 2021-10-11
SG11201610334XA (en) 2017-01-27
DK3164385T3 (en) 2021-10-11
NZ727251A (en) 2023-06-30
RU2016151637A3 (en) 2019-01-28
AU2015282909B2 (en) 2019-02-07
CA2951794C (en) 2023-03-07
WO2016001398A1 (en) 2016-01-07
JO3639B1 (en) 2020-08-27
ECSP17000222A (en) 2017-02-24
CA2951794A1 (en) 2016-01-07
CN112961095A (en) 2021-06-15
TWI665188B (en) 2019-07-11
JP2020059724A (en) 2020-04-16
SI3164385T1 (en) 2021-10-29
MA40345A (en) 2021-04-28
EP3164385B1 (en) 2021-09-08
CN112961094A (en) 2021-06-15
KR102399374B1 (en) 2022-05-17
SV2016005353A (en) 2017-03-23
TN2016000549A1 (en) 2018-04-04
AR101109A1 (en) 2016-11-23
JP6643330B2 (en) 2020-02-12
CO2017000019A2 (en) 2017-05-31
PH12016502477A1 (en) 2017-04-10
CL2017000002A1 (en) 2017-06-23
HUE056368T2 (en) 2022-02-28
PE20170522A1 (en) 2017-05-28
AP2016009643A0 (en) 2016-12-31
KR20170023019A (en) 2017-03-02
BR112017000127A2 (en) 2018-01-23
JP2017519829A (en) 2017-07-20
MY190715A (en) 2022-05-12
IL249428A0 (en) 2017-02-28
AU2015282909A1 (en) 2017-01-05
CN106458889A (en) 2017-02-22
HRP20211596T1 (en) 2022-01-07
US20170152227A1 (en) 2017-06-01
PH12016502477B1 (en) 2017-04-10
IL249428B (en) 2019-10-31
EA035894B1 (en) 2020-08-27
DOP2017000001A (en) 2017-03-31
RS62380B1 (en) 2021-10-29
PL3164385T3 (en) 2021-12-20
MA40345B1 (en) 2021-10-29
EA201692485A1 (en) 2017-05-31
PT3164385T (en) 2021-10-07
EP3164385A1 (en) 2017-05-10
RU2016151637A (en) 2018-08-08
CR20160605A (en) 2017-04-24
TW201625525A (en) 2016-07-16
ES2893619T3 (en) 2022-02-09
US10071963B2 (en) 2018-09-11
GEP20227368B (en) 2022-03-25
HRP20211596T8 (en) 2022-03-04
MX2016016895A (en) 2017-04-27
UA121547C2 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CL2020001852A1 (en) Processes for the preparation of s-ketamine or s-ketamine hydrochloride or products derived from it. (divisional request 201901066)
CY1121602T1 (en) COMPOSITION OF KOPANLISIMPI AND ITS DIHYDROCHLORATE
CY1120763T1 (en) NEW SULPHONYLAMINOVENZAMIDE COMPOUNDS
EA202190475A1 (en) MINI-GDE FOR TREATMENT OF GLYCOGENOSIS TYPE III
BR112017018993A2 (en) PROCESS TO PREPARE 3-CHLORINE-2-VINYLPHENYLSULPHONATES
MX2019004182A (en) Process for the manufacture of 2,6-dimethyl-5-hepten-1-al.
EA201691632A1 (en) PIRASINS AS GPR6 MODULATORS
CY1124594T1 (en) A NOVEL POLYMORPHIC FORM OF N-[2-(6-FLUORO-L-INDOL-3-YL)ETHYL]-3-(2,2,3,3-TETRAFLUOROPROPXY)BENZYLAMINE HYDROCHLORIDE FOR THE INDUCTION OF ALZHEIMER
MX2019002017A (en) Sofosbuvir derivatives for the treatment of hepatitis c.
EA201692246A1 (en) Method of producing 2,6-dimethylbenzoquinone
MX2017012960A (en) Method for producing acylsulfamoylbenzamides.
BR112016028698A2 (en) piperidine-4-carbothioamide preparation
MX2016012936A (en) Process for the preparation of n-[3-(benzylcarbamoyl)phenyl]-1 h-pyrazole-5-carboxamides.
IN2015CH02092A (en)
IT201700123558A1 (en) PROCESS FOR THE SYNTHESIS OF 2-BENZIDRIL-3 KINUCLIDINONE
BR112017014980A2 (en) method for preparing 4-cyanopiperidine hydrochloride.
BR112017018992A2 (en) process of preparing substituted phenylisoxazoline derivatives
MX2017011391A (en) Process for preparing piperidine-4-carbothioamide hydrochloride.
UA112041C2 (en) N- (4-TRIFLUOROMETHYLPHENYL) -4-HYDROXY-2,2-DIOXO-1H-2λ6,1-BENZOTHIAZINE-3-CARBOXAMID, WHICH HAS ANALGETIC ACTIVITY
BR112016028702A2 (en) process for preparing 3,5-bis (haloalkyl) pyrazole derivatives via hydrazone acylation
TR201819806T4 (en) Calebin A. for induction of lipolysis.
PL408984A1 (en) New analogues of 1,2,4-triazolophthalazines